Bazedoxifene is a third-generation selective oestrogen receptor modulator (SERM), which originated with Ligand Pharmaceuticals as TSE-424, a treatment for postmenopausal osteoporosis (PMO), and has been developed in an alliance which began in September 1994 with Wyeth-Ayerst Laboratories, of American Home Products (AHP).